Insights

The Pharmacy Times® Insights video library presents one-on-one interviews with pharmacy experts, who examine the latest patient counseling tools and innovative solutions for the everyday practice and business.

What can we help you find?
CINV
Bhavesh Shah, RPh, BCOP, and Katherine Lin, PharmD, BCOP, review the multidrug treatment approach and the unmet needs for chemotherapy-induced nausea and vomiting.
CINV Therapy
Experts in the management of chemotherapy-induced nausea and vomiting elaborate on patient factors that impact the treatment options for chemotherapy-induced nausea and vomiting.
CINV treatments
A discussion of appropriate early patient management of chemotherapy-induced nausea and vomiting and considering individualized care when deciding if patients need prophylactic treatment.
CINV treatments
Bhavesh Shah, RPh, BCOP, and Katherine Lin, PharmD, BCOP, provide input on individualizing early treatment for chemotherapy-induced nausea and vomiting.
CINV
A thorough review of the ancillary treatment options for chemotherapy-induced nausea and vomiting.
 
CINV
Experts in the management of chemotherapy-induced nausea and vomiting review the efficacy and safety of the available treatment options based on their mechanism of action.
 
Bhavesh Shah, RPh, BCOP, and Katharine Lin, PharmD, BCOP, elaborate on the impact chemotherapy-induced nausea and vomiting has on patients’ quality of life.
 
Economic Burden
A discussion on the economic burden of treating chemotherapy-induced nausea and vomiting.
 
CINV treatments
Bhavesh Shah, RPh, BCOP, and Katharine Lin, PharmD, BCOP, discuss the various treatment options, mechanism of action and dosing of agents used for chemotherapy-induced nausea and vomiting.
Treatment of CINV
A review of the guidelines and patient factors to determine the therapeutic agents used for prophylactic care for chemotherapy-induced nausea and vomiting.
 
Nausea & Vomiting
Experts in the management of chemotherapy-induced nausea and vomiting (CINV) provide a summary of the distinct types of CINV.
Utilizing a DOAC
Considerations for transitioning patients from heparin over to a direct oral anticoagulant for venous thromboembolism prophylaxis, and strategies that can help health care professionals better manage patients through a drug shortage.